EFNS guidelines on pharmacological treatment of neuropathic pain
By N. Attal, G. Cruccu, M. Haanpää, P. Hansson, T. S. Jensen, T. Nurmikko, C. Sampaio, S. Sindrup, P. Wiffen. European Journal of Neurology, 2006
1,060 citations recorded by the source corpus.
Subfields: Neurology, Pathology and Forensic Medicine, Physiology
View Paper: https://www.semanticscholar.org/paper/ccb8a2bbe55c43fd86413e1eba2162c1e6f8bcdc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
In Physiology
Citations in the corpus
- EFNS guidelines on neurostimulation therapy for neuropathic pain (2007, background): “Eligible patients should be resistant or intolerant to main drugs used for neuropathic pain [1,2].”
- Algorithm for neuropathic pain treatment: An evidence based proposal (2005, neutral): “The treatment of trigeminal neuralgia (tic douloureux), for which there are distinct treatment recommendations [3,65], was not considered.”
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). (2014, neutral): “%) relief from their chronic pain through pharmacological treatment (Attal et al., 2006).”
- AAN‐EFNS guidelines on trigeminal neuralgia management (2008, methodology): “In line with the recent EFNS Guidelines,[3] the two drugs to consider as first-line therapy in CTN are CBZ (200–1200 mg/day) and OXC (600–1800 mg/day).”
- Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome (2007, background): “Recent systematic reviews have reported that a minority of neuropathic pain patients obtain 50% or more pain relief with conventional pharmacologic management, a proportion of which experience significant side effects (Finnerup et al., 2005; Attal et al., 2006; Eriksen et al., 2006).”
- Pharmacologic management of neuropathic pain: Evidence‐based recommendations (2007, neutral): “The treatment of trigeminal neuralgia (tic douloureux), for which there are distinct treatment recommendations [3,65], was not considered.”